June 17, 2021 – 20:30
European Union countries should use all available coronavirus vaccine options available to fight the pandemic, the European Medicines Agency (EMA) said on Thursday (June 17th).
According to the European regulator, it is still too early to say whether a particular type of vaccine is the best, reports AFP.
Some countries have limited immunization with AstraZeneca and Johnson & Johnson vaccines due to blood clotting concerns. They are mainly developing the immunization campaign with Pfizer and Moderna vaccines.
“We are still in a pandemic and it is very important to use all the opportunities at our disposal to fight it,” Marco Cavaleri, EMA’s chief vaccine strategist, told a news conference.
The EMA expert added that it is “very difficult to say” which type of technology with which vaccines are produced may prove more successful in the future. According to him, all existing vaccines “have already saved thousands and millions of lives”.
EMA has authorized the use of four vaccines: Pfizer / BioNTech, Moderna, AstraZeneca and J&J.
One of the four other vaccines under review by this agency is Germany’s CureVac. Based on the test results it turned out that it was only 47 percent effective.
That figure is below the 50 percent efficiency threshold, but Cavaleri said “this does not mean the agency will not review the entirety of the evidence” before making a decision.
The European Medicines Agency (EMA) has said it will not set a 50 per cent efficacy threshold for coronavirus vaccines to be approved for use.